Migraines cause severe headaches paired with visual disturbances and neurological sensations. The medication ubrogepant, approved by the FDA in 2019, shows promise in alleviating not just headaches but also accompanying symptoms like photophobia and cognitive dysfunction. A recent study in Nature Medicine indicates ubrogepant may be effective even when taken early during the migraine prodrome phase, potentially helping those who experience symptoms before pain onset. Ongoing research aims to fully explore its effectiveness across variable migraine symptom timelines.
"The pain always travels in some way, and it's undeniably overwhelming," explained Terri Battenburg. "I usually just try to power through it, but it's like trying to swim through mud."
Given the variable timelines of when different symptoms begin, there's more research to do here, but these results may act as a balm to many people suffering from migraines.
A paper published earlier this month in Nature Medicine offers some encouraging news about the drug ubrogepant, which the authors concluded "may treat symptoms such as photophobia, phonophobia and cognitive dysfunction."
Collection
[
|
...
]